These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23890905)

  • 1. Revisiting evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration: fractional polynomials meta-regression of blood pressure reduction by angiotensin-converting enzyme inhibitors on stroke risk.
    Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
    Int J Cardiol; 2013 Oct; 168(4):4590-2. PubMed ID: 23890905
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration.
    Strauss MH; Lonn EM; Verma S
    Eur Heart J; 2005 Nov; 26(22):2351-3. PubMed ID: 16219656
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood pressure-dependent and independent effects of amlodipine and angiotensin receptor blockers on the risk of stroke.
    Takagi H; Umemoto T
    Int J Cardiol; 2011 Aug; 151(1):99-100. PubMed ID: 21645933
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary and secondary prevention of stroke by antihypertensive drug treatment.
    Wang JG; Li Y
    Expert Rev Neurother; 2004 Nov; 4(6):1023-31. PubMed ID: 15853529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 7. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
    J Hypertens; 1998 Feb; 16(2):127-37. PubMed ID: 9535138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke in chronic kidney disease: prevention and management.
    Townsend RR
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S11-6. PubMed ID: 18178791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood pressure lowering therapy for mild hypertensive patients with a history of stroke].
    Ishikawa E; Ibayashi S
    Nihon Rinsho; 2008 Aug; 66(8):1560-5. PubMed ID: 18700558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke.
    Angeli F; Gentile G; Reboldi G; Verdecchia P
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1171-4. PubMed ID: 18939903
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D; Hill MD
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher small arterial elasticity in hypertensive patients treated with angiotensin II receptor blockers.
    Takeuchi K; Ideishi M; Tashiro T; Morishige N; Yamada T; Saku K; Urata H
    Hypertens Res; 2005 Aug; 28(8):639-44. PubMed ID: 16392767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of stroke in patients with hypertension.
    Dahlöf B
    Am J Cardiol; 2007 Aug; 100(3A):17J-24J. PubMed ID: 17666193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant beneficial effect of AT-1 receptor blockers (sartans) in stroke.
    Al-Nimer MS
    Neurosciences (Riyadh); 2012 Jan; 17(1):6-15. PubMed ID: 22246005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Suzuki H; Kanno Y;
    Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
    Baumgart P
    MMW Fortschr Med; 2008 Jan; 150(1-2):52-3. PubMed ID: 18300647
    [No Abstract]   [Full Text] [Related]  

  • 19. [Blood pressure control in chronic stroke].
    Nagai M; Hoshide S; Kario K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():378-83. PubMed ID: 16981568
    [No Abstract]   [Full Text] [Related]  

  • 20. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.